kira6

Catalog No.S8658 Batch:S865802

Print

Technical Data

Formula

C28H25F3N6O
Molecular Weight 518.53 CAS No. 1589527-65-0
Solubility (25°C)* In vitro DMSO 50 mg/mL (96.42 mM)
Ethanol 25 mg/mL (48.21 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
1.25mg/ml
5% DMSO 95% Corn oil
1.25mg/ml
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description kira6 is a potent type II IRE1α kinase inhibitor with an IC50 of 0.6 μM. It dose-dependently inhibits IRE1α(WT) kinase activity, XBP1 RNA cleavage, Ins2 RNA cleavage and oligomerization.
Targets
IRE1α [1]
(Cell-free)
0.6 μM
In vitro

In INS-1 cells, KIRA6 inhibits IRE1α auto-phosphorylation by Tg and XBP1 mRNA splicing by Tm in a dose-dependent manner[1].
In vivo

Intravitreally, KIRA6 preserves photoreceptor functional viability in rat models of ER stress-induced retinal degeneration. Systemically, KIRA6 preserves pancreatic β-cells, increases insulin, and reduces hyperglycemia in Akita diabetic mice. KIRA6 inhibits IRE1α in vivo to preserve cell viability and function in diverse cells and rodent tissues experiencing ER stress. The pharmacokinetic profile of KIRA6 in BALB/c mice intraperitoneally (i.p.) dosed at 10 mg/kg shows good drug plasma AUC levels (AUC 0-24h = 14.3 μM*h) with moderate clearance (22.4 mL/min/kg). Drug half-life is 3.90 hours, Cmax is 3.3 μM, and plasma levels at 4 and 8hr are 1.2 μM and 0.33 μM, respectively[1].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    THP-1 cells

  • Concentrations

    0.5 μM

  • Incubation Time

    4 h

  • Method

    Cells were treated with various concentrations of drug.
Animal Study:

[1]
  • Animal Models

    BALB/c mice

  • Dosages

    10 mg/kg

  • Administration

    i.p.

Selleck's kira6 has been cited by 33 publications

The HRD1-SEL1L ubiquitin ligase regulates stress granule homeostasis in couple with distinctive signaling branches of ER stress [ iScience, 2024, 27(7):110196] PubMed: 38979013
Activation of the sigma-1 receptor ameliorates neuronal ferroptosis via IRE1α after spinal cord injury [ Brain Res, 2024, 1838:149011] PubMed: 38763502
Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity [ Cell Rep Med, 2023, S2666-3791(23)00373-7] PubMed: 37769655
Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity [ Cell Rep Med, 2023, 4(10):101206] PubMed: 37769655
Metastatic effects of environmental carcinogens mediated by MAPK and UPR pathways with an in vivo Drosophila Model [ J Hazard Mater, 2023, 441:129826] PubMed: 36084456
Inhibition of neutrophil extracellular trap formation ameliorates neuroinflammation and neuronal apoptosis via STING-dependent IRE1α/ASK1/JNK signaling pathway in mice with traumatic brain injury [ J Neuroinflammation, 2023, 20(1):222] PubMed: 37777772
Inhibition of neutrophil extracellular trap formation ameliorates neuroinflammation and neuronal apoptosis via STING-dependent IRE1α/ASK1/JNK signaling pathway in mice with traumatic brain injury [ J Neuroinflammation, 2023, 20(1):222] PubMed: 37777772
Neurotransmitter release progressively desynchronizes in induced human neurons during synapse maturation and aging [ Cell Rep, 2023, 42(2):112042] PubMed: 36701235
Inhibition of neutrophil extracellular trap formation attenuates NLRP1-dependent neuronal pyroptosis via STING/IRE1α pathway after traumatic brain injury in mice [ Front Immunol, 2023, 14:1125759] PubMed: 37143681
Inhibition of neutrophil extracellular trap formation attenuates NLRP1-dependent neuronal pyroptosis via STING/IRE1α pathway after traumatic brain injury in mice [ Front Immunol, 2023, 14:1125759] PubMed: 37143681

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.